Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma improves Aurum pre-filled syringe packaging
Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Packaging
PPWR: why interpretation and alignment matter more than awareness

PPWR: why interpretation and alignment matter more than awareness

Read more
The EU Packaging and Packaging Waste Regulation is often described as a packaging regulation. For pharmaceutical manufacturers, however, its implications extend well beyond packaging alone

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I) Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
  2. OPTIMA introduces FiberOne Pro for high-volume fiber-based packaging production The new platform is designed to transfer fiber packaging concepts into high-volume manufacturing. It is capable of producing up to 1,900 portion packs per minute, depending on application and material
  3. Navigating complexity in aseptic fill and finish Vetter’s Norbert Gerling discusses operational challenges, flexible manufacturing, automation and contamination control in sterile drug production
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I) With the right questions and scrutiny during procurement, organisations can avoid the over-engineering trap and select a QMS solution that fits their requirements and allows them to remain competitive
  5. Streamlining supply chains from clinical trial to commercial scale Vetter’s Ayse Hizli discusses commercial supply chain planning, digital visibility, resilience and cold-chain management from clinical development to market launch

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Packaging
PPWR: why interpretation and alignment matter more than awareness

PPWR: why interpretation and alignment matter more than awareness

The EU Packaging and Packaging Waste Regulation is often described as a packaging regulation. For pharmaceutical manufacturers, however, its implications extend well beyond packaging alone
Manufacturing
Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection

Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection

Joint system-level testing combines Stevanato's glass syringes with Aptar's elastomer components to provide key data earlier in development and inform packaging decisions for sensitive biologics and other injectable therapies
Manufacturing
Why CAPA keeps failing and what strong organisations do differently

Why CAPA keeps failing and what strong organisations do differently

This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
Manufacturing
Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Cloud-based environmental monitoring helps life science organisations establish professional-quality monitoring from day one and scale as requirements evolve
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)

How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
Packaging
More tubes, more choice: Recipharm expands sterile creams and ointments

More tubes, more choice: Recipharm expands sterile creams and ointments

Recipharm expands its sterile manufacturing capacity with a new cream and ointment line at Odivelas, Portugal, which is able to produce 8–15 million units per year
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)

Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
Subscribe now